Compare the questions first
BPC-157, GHK-Cu, retatrutide and tirzepatide often turn up together. That doesn’t mean their evidence belongs in one league table. I find it more useful to ask what kind of study sits behind each claim.
A cell experiment looks at a small part of the biology. Animal work can explore effects in a whole living animal. Neither tells us directly what a treatment does in people.
A small human pilot can raise a useful question. A controlled trial can compare outcomes between groups. The word study covers all of these, which is how very different findings end up sounding equally settled. When that word appears in a headline, I want the next sentence to tell me what sort of study it was. Otherwise the most useful detail has gone missing.
Four compound names don’t give us four comparable answers.
BPC-157 and GHK-Cu leave different gaps
For BPC-157, a research review describes promising animal work and very little human evidence. Only two people took part in the intravenous safety pilot, and each had tried BPC-157 intravenously before the study. It didn’t measure injury healing or safety in new users.
For GHK-Cu, matching the preparation is often the first problem. A hair-growth study used GHK without copper plus another ingredient. Its result can’t be handed over to injected GHK-Cu.
One gap is about how little has been studied in people. Another is about whether the study even tested the thing being discussed. A high purity figure solves neither.
“There’s a study” is the beginning of the reading.
Retatrutide and tirzepatide have different status
Retatrutide’s obesity trial and tirzepatide’s obesity trial both compared treatment with a dummy treatment in people. Their separate results don’t make a direct contest. Different participants and designs can change what the numbers mean.
Retatrutide remains investigational. Federal law rules out using it for compounding, FDA says. Tirzepatide has approved medicines, while compounded versions are not FDA-approved.
Safety isn’t a tie-breaker to add at the end. For BPC-157 and GHK-Cu injections, FDA points to impurities and possible immune reactions. Retatrutide’s trial reported stomach effects and increased heart rate. Tirzepatide’s label includes common stomach effects and serious warnings.
The quality page takes up the sample questions. A care decision also needs a clinician who can consider your health and medicines. These comparisons help you read the evidence without turning it into a recommendation to take something.
A useful comparison leaves the important differences visible.